Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study (Q45168352)
Jump to navigation
Jump to search
scientific article published in December 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study |
scientific article published in December 2004 |
Statements
1 reference
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study (English)
1 reference
F Duffaud
1 reference
M Borner
1 reference
P Chollet
1 reference
J B Vermorken
1 reference
J Bloch
1 reference
M Degardin
1 reference
F Rolland
1 reference
C Dittrich
1 reference
B Baron
1 reference
D Lacombe
1 reference
P Fumoleau
1 reference
EORTC-New Drug Development Group/New Drug Development Program
1 reference
1 December 2004
1 reference
1 reference
40
1 reference
18
1 reference
2748-2752
1 reference
Identifiers
1 reference
1 reference